the more visible move from regeneron. the treatment approved for diabetic macular edema. as much as i love this stock i thought it might be down more. i attribute the decline to sanafi which seems to buy that stock every time it goes down. every share in the company is they can buy more than they are already buying. i think they will continue to buy the rest of the company. today i realize the excitement comes from the possibility stemming from a formulation we don't talk about on the show which is being used to control asthma. put out a release describing how the positive effects of the drug were seen across a broad population in phase two b trials. this was unexpected by many people hence the analyst supports with titles i love. asthma data reinforces potential or home run in asthma. usually don't get that positive headlines. the drug can turn out to be wondrous as it is showing results against all sorts of allergic diseases including dermatitis and chronic rhino sinusitis. you tack these on to companies developing anticholesterol and it is clear regeneron is developing

. >>> regeneron released positive trial data on an experimental drug that treats moderate to severe asthma. >>> shares of zotis were higher on a report that an activist investor had taken a $2 billion stock in the company. he could push the animal health firm to sell itself to a larger drug plashg. that sent shares up almost 9% to $43.72. >>> after the bell, fossil impressed investors with its earnings report. the fashion accessories maker beat estimates and renewed a licensing agreement with michael kors to continue to create watches together. it's also authorizing a billion dollar stock buyback. fourth quarter guidance was a little less than expected but that didn't seem to plaert. shares surged initial lip after the bell up as much as 15% during regular trading shares were up slightly. they closed at $103.75. >>> are low interest rates making you nervous? well, charles flosser says they should make all of us nervous. today the president of the philadelphia federal reserve bank says that right now there is no reason to keep record-low interest rates at current crisis era levels. >> there

regeneron, not what i wanted. there is a guide down. >> there you go. makes up for discovery down 9%, sprint down. >> what is herbalife? >> herbalife -- >> down almost 15%. according to the "times" profile on ackman, this is about the price which bill begins to turn a profit on hlm. >> when you saw suntrust, there are guys who like this. i think the support is going to be evaporated here. you need to see better numbers. wasn't just venezuela, you know? >> that was a big part of it. >> venezuela, there's like $200 million they are never going to get back. if you look at -- clorox pulled out of venezuela. there are other companies that hang on betting that chavez would somehow, things would get better. things have gotten worse. venezuela is a great economy that these companies keep hoping comes back. >> has got a lot of oil. >> argentina, when they banned proctor. what is that? >> can we talk oil? that is the other story today. we watched it move well below $80. a lot of these names have been getting beat up. we talked about san bridge down. >> there are

regeneron, and argala, regeneron. >> dendreon, filing for chapter 11. >> a situation where retail investorse fascinate the with the drug provenge and it didn't work. it didn't price work. you have to recognize whether the diet pill, something that is just kind of looks like it's the magic bullet for the diseases, there are no magic bullets other than gilead's hep c. it cures. >> 180 million people around the world? >> it's been one of the things where the insurance companies are praying for alternative. they just keep thinking, if we can pit gilead against someone, if we can make it gilead doesn't have a monopoly, but a lot of the guys, listen, we're not paying but it's hard not to pay for a cure. it's a fatal disease. >> it is. meg tirrell, by the way, in boston, we might hear from her lateren on cramer's mad dash. one more look at the premarket on this monday. more "squawk on the street" from the nyse straight ahead. ♪ there's confidence... then there's trusting your vehicle maintenance to ford service confidence. our expertise, technology, and high quality parts means your peace of mind.

. >> david, regeneron has a powerful franchise, too.re you in terms of competing with them on 2015-2016? >> as you know we recently got the approval for diabetic macular edema, brought the label in the united states beginning of september, and sales have take ain't remarkable uptick since then. we believe somewhere between 30% to 40% of patients with diabetic macular edeem ma are insufficiently served alone. given our product dosed every four to five months you can imagine the convenience. further out, we have a great program, that's one i think is a sleeper. >> you've said that's -- the stock was at 80, david telling me, darpen valued less than zero. >> that was another point i had to make to brent to say, you know, you're getting this free of charge, to make him feel about 219. >> well, it's -- >> we're excited about darpen. >> this is a difficult battle i argue for you. you've been fighting here against valeant, ackman for some time, a great deal of vitriol to a certain extent from both sides. was there a point of which you realized

look at companies that have -- regeneron, regn, the fda will determine whether or not this cholesterolug will be approved and it is a blockbuster. charles: does either party matter with respect to approval? >> it does. the republican party is more pro-business and business-friendly. it seeps all the way down to the fda. this drug is proven. matter of getting politics aside. charles: carrie, you with wanted to chime in on too much money in politics. is there too much money in politics? >> well you mentioned, citizens united. charles: corporations. sure, are they people? >> are they people. this was ruling from the supreme court. this question is academic at this point. until we were to have some sort -- charles: it is academic but i it is academic, someone could campaign on that. elizabeth warren or hillary clinton saying that supreme court decided big buildings with people in them are people and have more rights than you do. not necessarily academic in my mind. >> constitution. how do you throw that in the waste bin. charles: i don't think, but believe me there are a lot of amendments

i don't need to be in a stock with a gigantic multiple like amazon when regeneron has a 35 multiple. that's the decision. people want to be in winners and are selling losers. suddenly netflix looks like a loser. it's the momentum guys. >> it's right at the cusp of being a loser for the year. >> isn't that something? you thought it was a winner. >> i did. >> these portfolio managers want to show how smart they are. they are going to buy apple. we on this show urged over and over again to own apple. >> hold it. >> yes. hold it. >> we've got more stocks to watch. the opening bell about four minutes away. then all the parts. come together, and there it is ... our new car! so, that's how santa fits it in his sleigh. wow ... wow. the magic of the season is here, at the lexus december to remember sales event. this is the pursuit of perfection. >>> you're watching cnbc "squawk on the street" live from the financial capital of the world. opening bell just about 60 seconds. if you missed revised gdp this morning it's 3.9%. revised up from 3.5%. we were only looking for 3.3%. we had two good qu

also, regeneron and sanofi. topper formers in the s&p 500, up by 3%. zynga higher after being upgraded to a buy rating from a hold citing the fast-growing mobile business and the popularity of words with friends. and then there's darden restaurants gaining ground after being upgraded of parent of olive garden citing the revamping of its menu offering and we'll end with groupon share advancing after a bullish shares outlook today and stock up by 5.5%. bill, kelly, on the day's trade. back over to you guys. >> thank you very much. >>> we're talking general electric right now. the company unveiled a new compensation plan for ceo jeff immelt and those unhappy with the long-term performance of ge stock calling for a change in the executive sweet and announcing a new plan, doesn't look like that's any time soon. >> well, after outperforming the dow last year ge had a disappointing 2014 down 6% and the overall market down 6%. will he reap the compensation three years from now? joining us is brian langenberg and david nelson. so, welcome to you both. david, th